| Background For a long time, chemotherapy plays an important role in the treatment of gynecological malignant tumors, and has been regarded as one of the three major treatments in the gynecological malignancies. However, Chemotherapy is a double-edged sword: as a systemic treatment, Chemotherapy can effectively control the growth, diffusion and transferability of malignant tumor, on the other hand, Chemotherapy also causes serious toxicity, permanent and irreversible damages such as Ovarian dysfunction and infertility which affect the life quality of patients seriously. Therefore, to protect the reproductive function of the patients during chemotherapy is very important.Studies showed that: Gonadotropin-releasing hormone agonist (GnRHa) has a protective effect on the chemotherapy caused ovarian damage in rats. GnRHa save the bulk of the primary follicles, reduce the damage of chemotherapy on rat ovarian and protect its reserving function. However, the application of GnRHa after chemotherapy, the reproductive function of rats and their offspring's development has less been reported. For this experimental research direction, to provide more breadboard evidence for further clinical research.Purpose(1) To study the effects of different doses of cyclophosphamide on fetal rat offspring.(2)To discussion the protective effect of GnRHa in reproductive function of chemotherapy-treated rat, observe visceral and skeletal dysplasia of offspring.Methods(1)Forty 2-3 months female SD rats whose weights were between (200±10)g were randomized into four groups of ten animals each group, the control group,CTX20mg/Kg group, CTX15mg/Kg group, CTX10mg/Kg group. All rats in this study were administered by intraperitoneal injection for 20d. Male and female rats mated by the ratio of 2:1 after administration, detection of sperm and suppository in vaginal smear vaginal next morning. The day as the "conception" date. On day 20 of gestation, all rats were sacrificed. Check the absorption of birth, still births and the number of live births after section, and records of live fetal rat fetal weight, length and tail length.(2)Forty 2-3 months female SD rats whose body weights were between(200±10)g were randomized into four groups of ten animals each group, the normal control group,CTX20mg/Kg group, GnRHa group and GnRHa+CTXgroup. All rats in this study were administered by intraperitoneal injection for 20d. Male and female rats mated by the ratio of 2:1 after administration, detection of sperm and suppository in vaginal smear vaginal next morning. The day as the conception date. On day 20 of gestation, all rats were sacrificed. Check the absorption of birth, still births and the number of live births after section, and records of live fetal rat fetal weight, length and tail length. To check fetal rat visceral and skeletal development through the Bouins and alizarin red solution.Results Compared with the control group: the body weight of three CTX dose groups rats have a certain degree of decline(P<0.05),15mg/kg and 10mg/kg groups have no significant difference(P>0.05).Each experimental group compared with control group, the live births and absorption rate have no significant difference(P>0.05), the stillbirth rate is significantly higher. Development indicators as fetal rat's body weight, body length, tail length has no significantly different (P> 0.05).Compared with the control group: CTX group loss weight obviously(P<0.05). CTX experimental group appeared fetal stillbirth and absorption, other experimental group have no fetal stillbirth and absorption. The stillbirth rate from the previous step is lower than the CTX20mg/kg experiment grpoup in the first step, absorption rate from the previous step is higher than CTX20mg/kg experiment grpoup in the first step Development indicators as fetal rat's body weight, body length, tail length have no significantly different (P> 0.05). Offspring of four groups had no obvious abnormalities.Conclusion In this experiment, 20mg/kg dose CTX cause offspring stillbirth and absorption, GnRHa was given before Cyclophosphamide can protect ovaries from chemotherapy-induced infertility, reduce stillbirth rate; the development of offspring have no obvious abnormalities. |
PDF Full Text Request